Matthew D. Galsky
Active 2005–2026
- 194
- Papers
- 29,795
- Citations
- 80
- h-index
- 177
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine74.7%
- Biochemistry, Genetics and Molecular Biology16.4%
- Immunology and Microbiology4%
- Engineering0.9%
- Psychology0.7%
- Materials Science0.6%
- Other2.7%
Topics
- Cancer Immunotherapy and Biomarkers11.5%
- Bladder and Urothelial Cancer Treatments9.4%
- Urinary and Genital Oncology Studies4.1%
- Ferroptosis and cancer prognosis3.3%
- Immunotherapy and Immune Responses3.2%
- COVID-19 and healthcare impacts2.5%
- Other66%
Coauthors
- John P. Sfakianos29
- William Oh27
- Andrea Necchi26
- Jonathan E. Rosenberg24
- Thomas Powles23
- Guru Sonpavde22
- Joaquim Bellmunt18
- Petros Grivas18
- Aristotelis Bamias17
- Daniel P. Petrylak17
- Dean F. Bajorin17
- Noah M. Hahn17
- Sumanta K. Pal16
- Sudeh Izadmehr15
- Matthew I. Milowsky14
- Nina Bhardwaj14
- Evan Y. Yu13
- Peter Wiklund13
- Ulka N. Vaishampayan13
- Li Wang12
- Reza Mehrazin12
- Cora N. Sternberg11
- Dingwei Ye11
- Padmanee Sharma11
All papers
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Authors: Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Dingwei Ye, Mads Agerbæk, Deborah Enting, Ray McDermott, Pablo Gajate, Avivit Peer, Matthew I. Milowsky, А. К. Носов, João Neif Antonio, Krzysztof Tupikowski, Laurence Toms, Bruce S. Fischer, Anila Qureshi, Sandra Collette, Keziban Ünsal-Kaçmaz, Edward Broughton, Dimitrios Zardavas, Henry Koon, Matthew D. Galsky - New England Journal of Medicine 2021 cited by 1,031
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Authors: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
Authors: Vaibhav G. Patel, William Oh, Matthew D. Galsky - CA A Cancer Journal for Clinicians 2020 cited by 1,133
- Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Authors: Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Gurkamal Chatta, Yüksel Ürün, Dingwei Ye, Zhisong He, Begoña P. Valderrama, Ja Hyeon Ku, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, M. PATEL, Federico Nasroulah, Matthew D. Galsky - New England Journal of Medicine 2023 cited by 462
- Bladder cancer
Authors: Lars Dyrskjøt, Donna E. Hansel, Jason A. Efstathiou, Margaret A. Knowles, Matthew D. Galsky, Jeremy Yuen‐Chun Teoh, Dan Theodorescu - Nature Reviews Disease Primers 2023 cited by 480
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Authors: Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias, Ian D. Davis, Maria De Santis, Eiji Kikuchi, Xavier García del Muro, Ugo De Giorgi, Marina Mencinger, Kouji Izumi, Stefano Panni, Mahmut Gümüş, Mustafa Özgüroğlu, Arash Rezazadeh Kalebasty, Se Hoon Park, B. Yа. Alekseev, Fabio A. Schutz, Jian-Ri Li, Dingwei Ye, Nicholas J. Vogelzang, Sandrine Bernhard, Darren Tayama, Sanjeev Mariathasan, Almut Mecke, AnnChristine Thåström, Enrique Grande - The Lancet 2020 cited by 787
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Authors: Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Bradley A. McGregor, Elisabeth I. Heath, Evan Y. Yu, Matthew D. Galsky, Noah M. Hahn, Elaina M. Gartner, Juan Pinelli, Shang-Ying Liang, Amal Melhem‐Bertrandt, Daniel P. Petrylak - Journal of Clinical Oncology 2019 cited by 626
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Authors: Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke, Ari David Baron, Andrea Necchi, Jens Bedke, Elizabeth R. Plimack, Daniel A. Vaena, Marc‐Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta K. Pal, Chikara Οhyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D. Galsky - The Lancet Oncology 2017 cited by 1,744
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Authors: Padmanee Sharma, Russell K. Pachynski, Vivek Narayan, Aude Fléchon, Gwénaëlle Gravis, Matthew D. Galsky, Hakim Mahammedi, Akash Patnaik, Sumit K. Subudhi, Marika Ciprotti, Burçin Şimşek, Abdel Saci, Yanhua Hu, G. Celine Han, Karim Fizazi - Cancer Cell 2020 cited by 393
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Authors: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Authors: Matthew D. Galsky, Noah M. Hahn, Jonathan Rosenberg, Guru Sonpavde, Thomas E. Hutson, William Oh, Robert Dreicer, Nicholas J. Vogelzang, Cora N. Sternberg, Dean F. Bajorin, Joaquim Bellmunt - Journal of Clinical Oncology 2011 cited by 688
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Authors: Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al‐Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Paweł Wiechno, Vagif Atduev, Ariel Galapo Kann, Tae‐Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, Mustafa Özgüroğlu, Bernhard J. Eigl, Niara Oliveira, Tomáš Büchler, Moran Gadot, Yousef Zakharia, J. Armstrong, Ashok Kumar Gupta, Stephan Hois, Michiel S. van der Heijden - New England Journal of Medicine 2024 cited by 322
- A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
Authors: Daniel J. Crona, Aimee Faso, Tomohiro F. Nishijima, Kathleen A. McGraw, Matthew D. Galsky, Matthew I. Milowsky - The Oncologist 2017 cited by 400
- Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Authors: Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez‐Kozlova, Kevin Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Cetnar, Brock O Neil, Anishka D'souza, Ronac Mamtani, Christos E. Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horowitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim‐Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John P. Sfakianos, Sumanta K. Pal - Nature Medicine 2023 cited by 133
- Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Authors: Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D. Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jérusalem, Seung Tae Kim, Keun‐Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J. Monk, Danny Nguyen, Do‐Youn Oh, Alicia Okines, David M. O’Malley, Paula R. Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cédric van Marcke, Evan Y. Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas E. Stinchcombe, Tanios Bekaii‐Saab - Journal of Clinical Oncology 2023 cited by 100
- Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
Authors: Timothy A. Yap, Aditya Bardia, Michael Dvorkin, Matthew D. Galsky, J. Thaddeus Beck, David R. Wise, O. B. Karyakin, Gábor Rubovszky, Nikolay Kislov, Kristoffer Staal Rohrberg, Anil A. Joy, Melinda L. Telli, Alison M. Schram, Umberto Conte, Colombe Chappey, Ross Stewart, Daria Stypinski, Elisabete Michelon, Rossano Cesari, Panagiotis A. Konstantinopoulos - JAMA Oncology 2022 cited by 100
- NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
Authors: Bérengère Salomé, John P. Sfakianos, Daniel Ranti, Jorge Daza, Christine Bieber, Andrew Charap, Christian Hammer, Romain Banchereau, Adam M. Farkas, Dan Fu Ruan, Sudeh Izadmehr, Daniel Geanon, Geoffrey Kelly, Ronaldo M. de Real, Brian Lee, Kristin G. Beaumont, Sanjana Shroff, Yuanshuo A. Wang, Ying‐Chih Wang, Tin Htwe Thin, Mónica Garcı́a-Barros, Everardo Hegewisch-Solloa, Emily M. Mace, Li Wang, Timothy J. O’Donnell, Diego Chowell, Rubén Fernández‐Rodríguez, Mihaela Skobe, Nicole Taylor, Seunghee Kim‐Schulze, Robert Sebra, Doug Palmer, Eleanor Clancy‐Thompson, Scott A. Hammond, Alice O. Kamphorst, Karl‐Johan Malmberg, Emanuela Marcenaro, Pedro Romero, Rachel Brody, Mathias Viard, Yuko Yuki, Maureen P. Martin, Mary Carrington, Reza Mehrazin, Peter Wiklund, Ira Mellman, Sanjeev Mariathasan, Jun Zhu, Matthew D. Galsky, Nina Bhardwaj, Amir Horowitz - Cancer Cell 2022 cited by 127
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Authors: Li Wang, Abdel Saci, Péter M. Szabó, Scott D. Chasalow, Mireia Castillo-Martín, Josep Domingo‐Domenech, Arlene O. Siefker‐Radtke, Padmanee Sharma, John P. Sfakianos, Yixuan Gong, Ana Dominguez-Andres, William Oh, David J. Mulholland, Alex Azrilevich, Liangyuan Hu, Carlos Cordon‐Cardo, Hélène Salmon, Nina Bhardwaj, Jun Zhu, Matthew D. Galsky - Nature Communications 2018 cited by 331
- What Is the Significance of Variant Histology in Urothelial Carcinoma?
Authors: Niyati Lobo, Shahrokh F. Shariat, Charles C. Guo, Mario I. Fernández, Wassim Kassouf, Ananya Choudhury, Jianjun Gao, Stephen B. Williams, Matthew D. Galsky, John A. Taylor, Morgan Rouprêt, Ashish M. Kamat - European Urology Focus 2019 cited by 244
- Selective PP2A Enhancement through Biased Heterotrimer Stabilization
Authors: Daniel Léonard, Wei Huang, Sudeh Izadmehr, Caitlin M. O’Connor, Danica Wiredja, Zhizhi Wang, Nilesh Zaware, Yinghua Chen, Daniela Schlatzer, Janna Kiselar, Nikhil Vasireddi, Stefan Schüchner, Abbey Perl, Matthew D. Galsky, Wenqing Xu, David L. Brautigan, Egon Ogris, Derek J. Taylor, Goutham Narla - Cell 2020 cited by 183
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Authors: Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih–Yuan Hsu, Aakash Desai, Gilberto Lopes, Petros Grivas, Corrie Painter, Solange Peters, Michael A Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii‐Saab, Mehmet Asım Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo and 136 more - The Lancet 2020 cited by 1,802
- ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Authors: Sangeeta Goswami, Yulong Chen, Swetha Anandhan, Péter M. Szabó, Sreyashi Basu, Jorge Blando, Wenbin Liu, Jan Zhang, Seanu Meena Natarajan, Liangwen Xiong, Baoxiang Guan, Shalini S. Yadav, Abdel Saci, James P. Allison, Matthew D. Galsky, Padmanee Sharma - Science Translational Medicine 2020 cited by 128
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
Authors: Matthew D. Galsky, Noah M. Hahn, Jonathan E. Rosenberg, Guru Sonpavde, Thomas E. Hutson, William Oh, Robert Dreicer, Nicholas J. Vogelzang, Cora N. Sternberg, Dean F. Bajorin, Joaquim Bellmunt - The Lancet Oncology 2011 cited by 345
